Literature DB >> 34209064

Antimicrobial Peptides and Physical Activity: A Great Hope against COVID 19.

Sonia Laneri1, Mariarita Brancaccio2, Cristina Mennitti2, Margherita G De Biasi1, Maria Elena Pero3, Giuseppe Pisanelli3, Olga Scudiero2,4,5, Raffaela Pero2,4.   

Abstract

Antimicrobial peptides (AMPs), α- and β-defensins, possess antiviral properties. These AMPs achieve viral inhibition through different mechanisms of action. For example, they can: (i) bind directly to virions; (ii) bind to and modulate host cell-surface receptors, disrupting intracellular signaling; (iii) function as chemokines to augment and alter adaptive immune responses. Given their antiviral properties and the fact that the development of an effective coronavirus disease 2019 (COVID-19) treatment is an urgent public health priority, they and their derivatives are being explored as potential therapies against COVID-19. These explorations using various strategies, range from their direct interaction with the virus to using them as vaccine adjuvants. However, AMPs do not work in isolation, specifically in their role as potent immune modulators, where they interact with toll-like receptors (TLRs) and chemokine receptors. Both of these receptors have been shown to play roles in COVID-19 pathogenesis. In addition, it is known that a healthy lifestyle accompanied by controlled physical activity can represent a natural weapon against COVID-19. In competitive athletes, an increase in serum defensins has been shown to function as self-protection from the attack of microorganisms, consequently a controlled physical activity could act as a support to any therapies in fighting COVID-19. Therefore, including information on all these players' interactions would produce a complete picture of AMP-based therapies' response.

Entities:  

Keywords:  COVID-19; antimicrobial peptide; cathelicidin; chemokine receptor; defensin; physical activity; toll-like receptor

Year:  2021        PMID: 34209064     DOI: 10.3390/microorganisms9071415

Source DB:  PubMed          Journal:  Microorganisms        ISSN: 2076-2607


  114 in total

Review 1.  Minireview: vitamin D receptor: new assignments for an already busy receptor.

Authors:  Anthony W Norman
Journal:  Endocrinology       Date:  2006-08-31       Impact factor: 4.736

2.  Vitamin D deficiency and insufficiency among US adults: prevalence, predictors and clinical implications.

Authors:  Xuefeng Liu; Ana Baylin; Phillip D Levy
Journal:  Br J Nutr       Date:  2018-04       Impact factor: 3.718

Review 3.  The Interplay between Defensins and Microbiota in Crohn's Disease.

Authors:  Lorena Coretti; Alessandro Natale; Mariella Cuomo; Ermanno Florio; Simona Keller; Francesca Lembo; Lorenzo Chiariotti; Raffaela Pero
Journal:  Mediators Inflamm       Date:  2017-01-26       Impact factor: 4.711

4.  SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels.

Authors:  Harvey W Kaufman; Justin K Niles; Martin H Kroll; Caixia Bi; Michael F Holick
Journal:  PLoS One       Date:  2020-09-17       Impact factor: 3.240

5.  A pneumonia outbreak associated with a new coronavirus of probable bat origin.

Authors:  Peng Zhou; Xing-Lou Yang; Xian-Guang Wang; Ben Hu; Lei Zhang; Wei Zhang; Hao-Rui Si; Yan Zhu; Bei Li; Chao-Lin Huang; Hui-Dong Chen; Jing Chen; Yun Luo; Hua Guo; Ren-Di Jiang; Mei-Qin Liu; Ying Chen; Xu-Rui Shen; Xi Wang; Xiao-Shuang Zheng; Kai Zhao; Quan-Jiao Chen; Fei Deng; Lin-Lin Liu; Bing Yan; Fa-Xian Zhan; Yan-Yi Wang; Geng-Fu Xiao; Zheng-Li Shi
Journal:  Nature       Date:  2020-02-03       Impact factor: 69.504

6.  Serum Levels of Vitamin C and Vitamin D in a Cohort of Critically Ill COVID-19 Patients of a North American Community Hospital Intensive Care Unit in May 2020: A Pilot Study.

Authors:  Cristian Arvinte; Maharaj Singh; Paul E Marik
Journal:  Med Drug Discov       Date:  2020-09-18

Review 7.  Accessory proteins of SARS-CoV and other coronaviruses.

Authors:  Ding Xiang Liu; To Sing Fung; Kelvin Kian-Long Chong; Aditi Shukla; Rolf Hilgenfeld
Journal:  Antiviral Res       Date:  2014-07-01       Impact factor: 5.970

Review 8.  SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far.

Authors:  Firas A Rabi; Mazhar S Al Zoubi; Ghena A Kasasbeh; Dunia M Salameh; Amjad D Al-Nasser
Journal:  Pathogens       Date:  2020-03-20

9.  Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial.

Authors:  Fanping Meng; Ruonan Xu; Siyu Wang; Zhe Xu; Chao Zhang; Yuanyuan Li; Tao Yang; Lei Shi; Junliang Fu; Tianjun Jiang; Lei Huang; Peng Zhao; Xin Yuan; Xing Fan; Ji-Yuan Zhang; Jinwen Song; Dawei Zhang; Yanmei Jiao; Limin Liu; Chunbao Zhou; Markus Maeurer; Alimuddin Zumla; Ming Shi; Fu-Sheng Wang
Journal:  Signal Transduct Target Ther       Date:  2020-08-27

Review 10.  Immunoinflammatory, Thrombohaemostatic, and Cardiovascular Mechanisms in COVID-19.

Authors:  Selin Gencer; Michael Lacy; Dorothee Atzler; Emiel P C van der Vorst; Yvonne Döring; Christian Weber
Journal:  Thromb Haemost       Date:  2020-10-29       Impact factor: 5.249

View more
  5 in total

1.  Improved Database Filtering Technology Enables More Efficient Ab Initio Design of Potent Peptides against Ebola Viruses.

Authors:  Thomas Ripperda; Yangsheng Yu; Atul Verma; Elizabeth Klug; Michellie Thurman; St Patrick Reid; Guangshun Wang
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-24

2.  dbAMP 2.0: updated resource for antimicrobial peptides with an enhanced scanning method for genomic and proteomic data.

Authors:  Jhih-Hua Jhong; Lantian Yao; Yuxuan Pang; Zhongyan Li; Chia-Ru Chung; Rulan Wang; Shangfu Li; Wenshuo Li; Mengqi Luo; Renfei Ma; Yuqi Huang; Xiaoning Zhu; Jiahong Zhang; Hexiang Feng; Qifan Cheng; Chunxuan Wang; Kun Xi; Li-Ching Wu; Tzu-Hao Chang; Jorng-Tzong Horng; Lizhe Zhu; Ying-Chih Chiang; Zhuo Wang; Tzong-Yi Lee
Journal:  Nucleic Acids Res       Date:  2022-01-07       Impact factor: 16.971

3.  Diagnostic and Therapeutic Potential for HNP-1, HBD-1 and HBD-4 in Pregnant Women with COVID-19.

Authors:  Mariarita Brancaccio; Cristina Mennitti; Mariella Calvanese; Alessandro Gentile; Roberta Musto; Giulia Gaudiello; Giulia Scamardella; Daniela Terracciano; Giulia Frisso; Raffaela Pero; Laura Sarno; Maurizio Guida; Olga Scudiero
Journal:  Int J Mol Sci       Date:  2022-03-22       Impact factor: 5.923

4.  Defensins: Therapeutic molecules with potential to treat SARS-CoV-2 infection.

Authors:  Sarena Banu; Ramakrishnan Nagaraj; Mohammed M Idris
Journal:  Indian J Med Res       Date:  2022-01       Impact factor: 5.274

Review 5.  Antimicrobial Peptides: From Design to Clinical Application.

Authors:  Chunye Zhang; Ming Yang
Journal:  Antibiotics (Basel)       Date:  2022-03-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.